Daniela Rothschild-Rodriguez, Kai S Lambon, Simran Krishnakant Kushwaha, Sofya K. Garushyants, Moritz Ertelt, Agnieszka Łątka, Ana Rita Costa, Anna Mantzouratou, Claire King, Dimitri Boeckaerts, Elizabeth Sheridan, Eugene V. Koonin, Francesca Merrick, Francis Drobniewski, Ilaria De Angelis, Kordo Saeed, Macy Martin, J. Mark Sutton, Matthew E. Wand, Michael Andrew, Morgen Hedges, Stan J. J. Brouns, Pieter‐Jan Haas, Sophie T Lawson, Stephen Mark Edward Fordham, Yan‐Jiun Lee, Yi Wu, Yves Briers, Peter Braun, Peter Weigele, Franklin L. Nóbrega
The growing threat of multidrug-resistant Klebsiella pneumoniae, coupled with its role in gut colonisation, has intensified the search for new treatments, including bacteriophage therapy. Despite increasing documentation of Klebsiella-targeting phages, clinical applications remain limited, with key phage-bacteria interactions still poorly understood. A major obstacle is fragmented access to well-characterised phage-bacteria pairings, restricting the collective advancement of therapeutic and mechanistic insights. To address this gap, we created the Klebsiella Phage Collection (KlebPhaCol), an open resource comprising 52 phages and 74 Klebsiella isolates, characterised at phenotypic and genomic levels. These phages span six families-including a novel family, Felixviridae, associated with the human gut-and target 20 sequence types (including ST258, ST11, and ST14) and 19 capsular-locus types (including KL1 and KL2), across 6 Klebsiella species. Freely accessible at www.klebphacol.org, KlebPhaCol invites the scientific community to both use and contribute to this resource, fostering collaborative research and a deeper understanding of Klebsiella-phage interactions beyond therapeutic use.